Try our Advanced Search for more refined results
May 23, 2014
AstraZeneca AB v. Aurobindo Pharma Ltd. et al
Case Number:
1:14-cv-00664
Court:
Nature of Suit:
Judge:
Firms
- Eckert Seamans
- Faegre Drinker
- Heyman Enerio
- McCarter & English
- Morris James
- Phillips McLaughlin
- Potter Anderson
- Richards Layton
- Shaw Keller
- White and Williams
- Whiteford Taylor
- Young Conaway
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- AstraZeneca PLC
- Aurobindo Pharma Ltd.
- Glenmark Pharmaceuticals Ltd.
- Par Pharmaceutical Cos. Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Bio AG
- Wockhardt USA LLC
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 03, 2017
AstraZeneca Prevails In Trial Over Diabetes Drug Patent
A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza and Kombiglyze XR were not invalid for being obvious, though he denied the pharmaceutical company's request for attorneys' fees in its suit against generic drug makers.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login